Literature DB >> 28921205

Effects and interaction of nicardipine and volatile anesthetics in the rat heart-lung preparation.

Satoshi Kashimoto1, Toshihiro Nakamura1, Masaki Kume1, Akihiko Nonaka1, Teruo Kumazawa1.   

Abstract

The effects of the calcium channel blocker nicardipine (N) and the volatile anesthetics halothane (H), enflurane (E), isoflurane (I), and sevoflurane (S) on myocardial metabolism after postischemic reperfusion were assessed in the isolated rat heart-lung preparation. Wistar-ST rats were randomly divided into six groups (each groupn=9) as follows: control (C) group, no drugs; N group, N (100 ng·ml-1); H group, 1% H and N; E group, 2.2% E and N; I group, 1.5% I and N; and the S group, 3.3% S and N. In the presence of the volatile anesthetics, the preparations were perfused for 10 min, made globally ischemic for 8 min, and then reperfused for 10 min. N 100 ng·ml-1 was administered 5 min before ischemia except in the C group. Three hearts in the C and H groups (eachn=9) and one heart in the E group (n=9) failed to recover from ischemia. The recovery times in the N, I and S groups were significantly shorter than controls. Although there was no significant difference in myocardial lactate concentrations among the groups, ATP content in the N, H, E, I and S groups was significantly higher than in controls. Glycogen content in the N, E, I and S groups was also significantly higher than in controls. These results suggest that N improves myocardial recovery from ischemia; however, in the presence of H or E it may cause significant myocardial depression.

Entities:  

Keywords:  Myocardial energy metabolism; Nicardipine; Volatile anesthetics

Year:  1994        PMID: 28921205     DOI: 10.1007/BF02482760

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  33 in total

1.  [New values for the molar extinction coefficients of NADH and NADPH for the use in routine laboratories (author's transl)].

Authors:  H U Bergmeyer
Journal:  Z Klin Chem Klin Biochem       Date:  1975-11

2.  The comparative cardiovascular effects of sevoflurane with halothane and isoflurane.

Authors:  T Kazama; K Ikeda
Journal:  J Anesth       Date:  1988-03-01       Impact factor: 2.078

3.  Pharmacological evaluation of YC-93, a new vasodilator, in healthy volunteers.

Authors:  T Seki; T Takenaka
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-06

4.  The effect of halothane, enflurane, and isoflurane on the dynamic stiffness of rabbit papillary muscle.

Authors:  T Shibata; T J Blanck; K Sagawa; W Hunter
Journal:  Anesthesiology       Date:  1989-03       Impact factor: 7.892

5.  Effects and interaction of verapamil and volatile anesthetics on the isolated perfused guinea pig heart.

Authors:  J Marijic; Z J Bosnjak; D F Stowe; J P Kampine
Journal:  Anesthesiology       Date:  1988-12       Impact factor: 7.892

6.  Haemodynamic dose-response effects of i.v. nicardipine in coronary artery disease.

Authors:  B Silke; S P Verma; G I Nelson; M Hussain; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

7.  Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Authors:  A Iliopoulou; P Turner; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

8.  Systemic and regional hemodynamics of isoflurane and sevoflurane in rats.

Authors:  P F Conzen; B Vollmar; H Habazettl; E J Frink; K Peter; K Messmer
Journal:  Anesth Analg       Date:  1992-01       Impact factor: 5.108

9.  Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease.

Authors:  B Silke; D J Graham; S P Verma; G Reynolds; M A Frais; J R Finlayson; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem.

Authors:  R P Hof
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.